Introduction
Despite the excellent response to frontline therapy with imatinib and second generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib [1] [2] [3] [4] , some patients with chronic myeloid leukemia (CML) fail to response to therapy and have poor long-term outcome 5 . It has been suggested that the achievement of early response to TKIs is a major determinant for long-term outcome [6] [7] [8] [9] .
The assessment of cytogenetic or molecular response at 3 months has been defined as a strong predictor for outcome of patients treated with frontline TKIs 6, [8] [9] [10] [11] [12] . Patients who do not achieve a major cytogenetic response (MCyR) or BCR-ABL transcript level <10% at 3 months have inferior event-free survival (EFS) and perhaps overall survival (OS) [10] [11] [12] . It is currently debated whether this finding is enough to justify a change in therapy for such patients.
The purpose of this analysis is to define whether additional assessment at 6 months may improve the ability to identify those patients destined to have a poor long-term outcome among those with a poor response at 3 months.
Methods

Patients
Between July 2000 and June 2011, a total of 456 newly diagnosed CML patients in chronic phase (CP) were treated at MD Anderson Cancer Center with: imatinib 400 mg daily (n=67), imatinib 800 mg daily (n=196), or second generation TKIs (2 nd GTKIs, dasatinib and nilotinib, n=193) in consecutive or parallel trials. All trials were approved by the institutional review board (IRB) and all patients signed informed consent in accordance with the Declaration of Helsinki.
Cytogentic and molecular responses were generally evaluated at baseline and every 3 month for the first year and then every 6 month. Cytogenetic responses were defined as described previously 13 .
Statistical analysis
Differences among variables were evaluated by the Fisher exact test for categorical and MannWhitney U test for continuous variables. Time-to-event analyses were performed by the KaplanMeier method, and survival curves were compared with the log rank test. All P values were two sided and values less than 0.05 were considered to be significant.
Results and Discussion
Among 456 patients treated, 44 (10%) did not achieve continued to have no MCyR, 2 (5%) had inevaluable cytogenetic analysis, and 6 (14%) were off study: one transformed to blast phase at 3 months; one changed therapy (to dasatinib) at 3 months because of lack of complete hematologic response (CHR) on imatinib 400, achieved a CCyR, and subsequently received a matched unrelated donor allogeneic stem cell transplant with ongoing complete molecular response (CMR) for over 6 years; one initially achieved CHR on nilotinib and then lost it, had irregular follow-up because of noncompliance, and subsequently received hydroxyurea for white blood cell count control and more recently started dasatinib; and 3 were lost to follow-up. Among patients with low and intermediate Sokal score at baseline who did not achieve MCyR at 3 months, 9/17 (53%, 4 CCyR and 5 PCyR) and 8/16
(50%, 3 CCyR and 5 PCyR) achieved a MCyR at 6 months, respectively; however only 2/11 (18%, 1 CCyR and 1PCyR) patients with high risk Sokal were able to achieve this response at 6 month.
During the first 6 months of therapy, 23 (52%) of the 44 patients required dose interruption of their initial therapy due to side effects (4 on imatinib 400, 14 imatinib 800, and 5 2 nd GTKI). Among them, 11 (48%) patients required dose interruption in the first 3 months, 6
(26%) between 3-6 months, and 6 (26%) in both periods. Median duration of interruption was 19 days (range, 1-59). Thirteen (30%) patients required dose reduction of their original dose during the first 6 months, 8 (62%) during the first 3 months, 4 (31%) between 3-6 months, and 1 (7%) in both periods.
With a median follow up of 95 months, the OS, failure free survival (FFS) and transformation free survival (TFS) for patients who did not achieve MCyR at 3 months and subsequently achieved a MCyR at 6 months were very similar to those of patients who achieved a MCyR at 3 months, and superior to that of patients still with no MCyR at 6 months (Firgure1).
The identification of the prognostic significance of response to TKI 3 months after the start of therapy has triggered a controversy as to the optimal management of these patients.
There is no currently available data from prospective studies suggesting change of therapy among these patients alters the outcome. The NCCN has recommended that these patients should be offered a change of therapy, with no option for continuation of therapy. However, only approximately 20% of those who have a poor response at 3 months have a poor outcome (i.e., an "event") and up to 10% of those with a good outcome at 3 months still have a poor long-term outcome. Thus, a change for all would be aimed at helping only 10-15% of patients. In this analysis we attempted to determine whether an additional observation at 6 months might better discriminate those patients destined to have a poor outcome. Indeed, those who still have not achieved a MCyR (currently considered suboptimal response by ELN 13 ) have a poor outcome, whereas those who by then have achieved MCyR have an excellent outcome. In our series only one patient progressed to blast phase and this occurred at 3 months, with no transformations occurring between 3-6 months. Our patient population had a higher percentage of patients with low risk Sokal score at baseline than what has been reported in other series. This score seems to be a good surrogate to predict the response at 3 and 6 months. Patients with high risk Sokal score at baseline had a higher chance of failing to achieve MCyR at 3 month. Moreover, among patients with high risk score who achieve MCyR at 3 month only 18% of them may subsequently achieve this response at 6 months suggesting that Sokal score may be helpful to identify those patients with the worse outcome that may need different approach. In contrast to our data, a recent series suggested that waiting for 6 months does not offer additional discrimination 14 , although the cutoff sought at 6 months was different (BCR-ABL 1%, grossly equivalent to CCyR 15 ). The differences between these two analyses can only be sorted by prospective studies that investigate these options and the long-term value of change of therapy versus continuation for patients with poor response at 3 months. Until such studies are available, it appears sensible to monitor patients closely and continue therapy for at least 3 more months.
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